

Disclosures

Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Amgen Inc.	Other - <i>Steering committee epidemiological/implementation research</i>	None (\$0)	Prevention
Amgen Inc.	Data Safety Monitoring Board	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	None (\$0)	Prevention
Heartflow	Other - <i>Steering committee atherosclerosis imaging management research</i>	None (\$0)	Prevention
Ionis	Other - <i>writing team, epidemiology of hypertriglyceridemia</i>	None (\$0)	Prevention
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
National Lipid Association † <i>Chief Science Officer - no direct funding from commercial source for this position</i>	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	Prevention

Clinical Trial Enroller (10)

Trial Name	Trial Sponsor	Trial Funding Source
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke	Amgen Inc.	
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia (MUIR)	arrowhead	
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk (ACCLAIM-CTA)	Eli Lilly and Company	
AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management (DECIDE)	Heartflow	
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)	Ionis	
olezarsen OLE	Ionis	
horizon	Novartis Corporation	
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis	Novartis Corporation	
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)	Novartis Corporation	
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease	Verve	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2024	failure to prevent coronary stent restenosis	Defendant † <i>N/A</i>	55 yo w/multiple metabolic risk factors s/p multiple DES s/p AMI; Cardiologist deescalated dual pathway inhibitor. Coronary stent restenosis occurred.	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/5/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/5/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 7/5/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 8/10/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.